Vinblastine

Generic Name
Vinblastine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C46H58N4O9
CAS Number
865-21-4
Unique Ingredient Identifier
5V9KLZ54CY
Background

Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Indication

For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Associated Conditions
Advanced Soft Tissue Sarcoma, Autoimmune Hemolytic Anemia, Bladder Cancer, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Letterer-Siwe disease, Metastatic Melanoma, Non-Small Cell Lung Cancer (NSCLC), Advanced Alibert-Bazin syndrome, Advanced Testicular cancer, Histiocytic lymphoma, Refractory Breast cancer
Associated Therapies
-
Clinical Trials
Related News

Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

First Posted Date
2015-01-22
Last Posted Date
2023-08-04
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
7
Registration Number
NCT02343718
Locations
🇨🇦

Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

🇨🇦

CHU Sainte-Justine, Montreal, Quebec, Canada

🇨🇦

Hospital for Sick Children, Toronto, Ontario, Canada

and more 3 locations

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.

First Posted Date
2014-11-18
Last Posted Date
2022-08-19
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
170
Registration Number
NCT02292979
Locations
🇳🇱

Reinier De Graaf Gasthuis, Delft, Netherlands

🇩🇰

Rigshospitalet, Copenhagen, Denmark

🇫🇷

CHU de Clermont-Ferrand, Clermont-Ferrand, France

and more 62 locations

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

First Posted Date
2014-07-31
Last Posted Date
2023-03-23
Lead Sponsor
North American Consortium for Histiocytosis
Target Recruit Count
1400
Registration Number
NCT02205762
Locations
🇺🇸

Children's Medical Center Dallas, UT Southwestern, Dallas, Texas, United States

🇺🇸

Children's Hospital of Los Angeles, Los Angeles, California, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 35 locations

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

First Posted Date
2014-07-04
Last Posted Date
2023-11-28
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
294
Registration Number
NCT02181738
Locations
🇺🇸

Local Institution - 0025, Boston, Massachusetts, United States

🇮🇹

Local Institution - 0019, Bologna, Italy

🇬🇧

Local Institution - 0026, Oxford, Oxfordshire, United Kingdom

and more 35 locations

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

First Posted Date
2014-06-30
Last Posted Date
2024-06-11
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
237
Registration Number
NCT02177695
Locations
🇺🇸

Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States

🇺🇸

Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States

🇺🇸

Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States

and more 563 locations

Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults

First Posted Date
2013-06-27
Last Posted Date
2022-05-31
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
144
Registration Number
NCT01887522
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

🇨🇭

Swiss Pediatric Oncology Group, Bern, Switzerland

🇬🇧

Cancer Research UK Clinical Trials Unit School of Cancer Sciences University of Birmingham, Edgbaston, Birmingham, United Kingdom

and more 5 locations

Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults

First Posted Date
2013-06-24
Last Posted Date
2022-05-27
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
35
Registration Number
NCT01884922
Locations
🇨🇭

Swiss Pediatric Oncology Group, Bern, Switzerland

🇳🇱

Erasmus MC/Sophia Children's Hospital, Rotterdam, Netherlands

🇬🇧

Cancer Research UK Clinical Trials Unit School of Cancer Sciences University of Birmingham, Edgbaston, Birmingham, United Kingdom

and more 5 locations

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

First Posted Date
2013-01-18
Last Posted Date
2024-08-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
41
Registration Number
NCT01771107
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Virginia Mason Medical Center, Seattle, Washington, United States

🇺🇸

Fred Hutchinson Cancer Center, Seattle, Washington, United States

and more 25 locations

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

First Posted Date
2012-10-23
Last Posted Date
2024-02-20
Lead Sponsor
Takeda
Target Recruit Count
1334
Registration Number
NCT01712490

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

First Posted Date
2012-10-04
Last Posted Date
2022-09-28
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
80
Registration Number
NCT01700946
Locations
🇺🇸

Rady Children's Hospital and Health Center, San Diego, California, United States

🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

🇺🇸

Cook Children's Medical Center, Fort Worth, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy